Literature DB >> 1983861

Delayed cardiac toxicity from anthracycline therapy.

L Steinherz1, P Steinherz.   

Abstract

Survivors of childhood cancer who received anthracycline treatment have a high incidence of abnormal cardiac function. Cardiac decompensation and death can appear many years after completion of chemotherapy. These survivors require periodic evaluation of cardiac function and rhythm.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1983861

Source DB:  PubMed          Journal:  Pediatrician        ISSN: 0300-1245


  16 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

3.  Anthracycline-induced cardiomyopathy.

Authors:  N G Fisher; A J Marshall
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

Review 4.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

Review 5.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 6.  Cardiotoxicity of HER2-targeted therapies.

Authors:  Robert S Copeland-Halperin; Jennifer E Liu; Anthony F Yu
Journal:  Curr Opin Cardiol       Date:  2019-07       Impact factor: 2.161

Review 7.  Sudden adult death.

Authors:  Neil E I Langlois
Journal:  Forensic Sci Med Pathol       Date:  2009-07-18       Impact factor: 2.007

8.  ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress.

Authors:  Yawen Gao; Yan Xu; Songwen Hua; Shenghua Zhou; Kangkai Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 9.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

Review 10.  Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.

Authors:  Rejane F Dillenburg; Paul Nathan; Luc Mertens
Journal:  Eur J Pediatr       Date:  2013-01-30       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.